Efficacy and safety of first-line osimertinib monotherapy versus osimertinib plus platinum-based chemotherapy or amivantamab plus lazertinib in metastatic EGFR-mutated NSCLC: an indirect comparison

BackgroundOsimertinib (Osi) has long represented the standard first-line treatment for metastatic EGFR-mutated non-small cell lung cancer. Recently, two randomized phase 3 trials demonstrated that osimertinib plus platinum-based chemotherapy (Osi+CT) and amivamtamab plus lazertinib (Ami+Laz) improve...

Description complète

Détails bibliographiques

Auteurs principaux:	Luna Del Bono, Andrea Ossato, Lorenzo Gasperoni, Stefano Vecchia, Luca Cancanelli, Vera Damuzzo, Stefania Gori, Roberto Tessari, Teodoro Sava, Alessandro Inno
Format:	Artigo
Langue:	Inglês
Publié:	Frontiers Media S.A. 2026-05-01
Collection:	Frontiers in Oncology
Sujets:	amivantamab EGFR-mutated NSCLC first-line therapy indirect treatment comparison lazertinib network meta-analysis
Accès en ligne:	https://www.frontiersin.org/articles/10.3389/fonc.2026.1802008/full
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!